• Kobayashi Pharmaceutical 1H net sales rose 2.5% to JPY 70.75 billion, while operating profit dropped 67.5% to JPY 2.16 billion.
• Ordinary profit fell 58.5% to JPY 3.01 billion; profit attributable to owners of parent slid 64.1% to JPY 1.14 billion.
• Extraordinary losses narrowed to JPY 1.64 billion from JPY 3.18 billion, as loss on product recall eased to JPY 661 million.
• Operating cash flow shrank to JPY 460 million from JPY 14.21 billion, while cash and cash equivalents ended at JPY 50.8 billion.
• Full-year forecast kept net sales at JPY 173 billion, operating profit at JPY 12.5 billion; dividend outlook maintained at JPY 106 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kobayashi Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.